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ABSTRACT 
Background: Quality of life (QOL) is impaired in functional dyspepsia (FD). 
Little is known about the effects of different therapies on the QOL profile in 
patients with this condition. 
Objectives: The aims of this study were to measure baseline QOL in patients 
with FD and to assess changes in QOL over time associated with Helicobacter 
pylori eradication and prokinetic treatment. The primary and secondary end 
points were the improvement in QOL 6 weeks and 1 year after successful eradi- 
cation of the infection or prokinetic therapy. 
Methods:  This 1-year, single-center, prospective, open-label, controlled, 
parallel-group trial was conducted at the Department of Gastroenterology, 
Ferencv~ros Health Centre, Budapest, Hungary. The Functional Digestive 
Disorder Quality of Life (FDDQoL) Questionnaire (MAPI Research Institute, Lyon, 
France) was translated and validated previously in Hungarian. Male and female 
subjects aged 20 to 60 years were enrolled and classified as H pylori positive 
(HP+), H pylori negative (HP-) with FD, or healthy (control group). The HP+ 
patients received pantoprazole 40 mg BID + amoxicillin 1000 mg BID + clar- 
ithromycin 500 mg BID for 7 days, followed by on-demand ranitidine (150- 
300 mg/d) for 1 year. The HP- patients received the prokinetic isapride 10 mg 
TID for 1 month, followed by on-demand cisapride (10-20 mg/d) for 1 year. The 
FDDQoL questionnaire was completed by all3 groups on enrollment, at 6 weeks, 
and 1 year. 
Results: A total of 101 HP+ patients, 98 HP- patients, and 123 healthy con- 
trois were included in the study (185 women, 137 men; mean age, 39.0 years). 
The mean (SD) baseline QOL scores were significantly lower in the HP+ group 
(53.3 [9.6]; 95% CI, 54.4-58.2) and the HP- groups (50.0 [9.8]; 95% CI, 58.0-62.0) 
compared with that in healthy controls (76.2 [8.7]; 95% CI, 74.6-77.8) (both, P< 
0.001). Analysis of the short-term domain scores found that the HP+ group had 
significantly decreased scores in 6 of 8 domains: daily activities (P = 0.005), 
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anxiety level (P = 0.02), diet (P = 0.008), sleep (P < 0.001), discomfort (P = 0.004), 
and disease control (P = 0.02); the HP- group had significantly decreased scores in 
5 of 8 domains: daily activities (P< 0.001), diet (P= 0.004), sleep (P = 0.005), dis- 
comfort (P < 0.001), and disease control (P = 0.02). Eradication of the infection 
was successful in 77/101 (76.2%) of the patients on intent-to-treat nalysis and 
77/94 (81.9%) on per-protocol analysis. Eradication was associated with an in- 
crease in mean (SD) QOL score to 70.8 (10.7) at 6 weeks (95% CI, 63.3-73.2; P < 
0.001 vs baseline) and to 75.3 (9.3) at i year (95% CI, 73.2-77.5; P = 0.05 vs 6weeks). 
In the HP- group, the QOL score increased to 73.3 (9.7) (95% CI, 71.3-75.4; 
P < 0.001 vs baseline) at 6 weeks of cisapride treatment and to 76.5 (8.5) at 
1 year (95% CI, 74.5-78.4; P = 0.06 vs 6 weeks). Most of the impaired domain 
scores improved significantly after both treatments. The short-term effect size 
was 1.48 in HP+ and 1.35 in HP- patients. Adverse events (AEs) occurred in 
22 (21.8%) patients in the HP+ group (nausea, 8 [7.9%] patients; diarrhea, 5 
[5.0%]; loss of appetite, 5 [5.0%]; stomatitis, 5 [5.0%]; abdominal pain, 4 [4.0%]; 
bloating, 4 [4.0%]; headache, 4 [4.0%]; vomiting, 4 [4.0%]; constipation, 3 [3.0%]; 
and vaginitis, 3 [3.0%]). In HP- cases, AEs occurred in 9 (9.2%) patients (abdom- 
inal cramps, 7 [7.1%]; diarrhea, 4 [4.1%]; and nausea, 3 [3.1%]). 
Conclusion:  In this study in patients with FD and healthy controls, eradication 
of H pylori infection in infected patients and cisapride treatment in uninfected 
patients reversed low QOL scores during the 1-year follow-up period. (Curr Ther 
Res Clin Exp. 2006;67:305-320) Copyright © 2006 Excerpta Medica, Inc. 
Key words: eradication, functional dyspepsia, Helicobacter pylori, prokinetics, 
quality of life. 
INTRODUCTION 
Dyspepsia has a prevalence of 25% in Western countries. Despite the many 
attempts to define the disease, it remains a poorly defined, misunderstood con- 
dition. 1 In Europe, the Rome II criteria have been used in clinical trials of anti- 
dyspepsia treatments. 2 Most dyspeptic patients do not have structural abnor- 
malities that account for their symptoms and thus are considered to have 
functional dyspepsia (FD). While FD has not been associated with mortality and 
complications, an outcome assessment using quality-of-life (QOL) instruments 
is recommended in these patients. 
In the past, the results of drug treatment trials in FD may have been 
biased by the variability of the inclusion criteria, the heterogeneity of FD 
(ulcerlike, dysmotility-like, or mixed types), the high rate of placebo 
response (40%-70%), and differences in outcomes evaluations (symptom 
grading or general or disease-specific QOL instruments). The results may 
also have varied according to the research setting; disease severity and treat- 
ment outcomes may have differed in patients treated as secondary or terti- 
ary referrals compared with those treated in a primary care setting. 1 
Helicobacter pylori is encountered in 30% to 50% of individuals with FD, but 
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its pathogenetic implications are far from clear, and evidence of the benefits 
of eradication is equivocal. 1,2 
The aims of this study were to measure baseline QOL in patients with FD and 
to assess changes in QOL over time associated with H pylori eradication and 
prokinetic treatment. The primary and secondary end points were the improve- 
ment in QOL 6 weeks and 1 year after successful eradication of the infection or 
prokinetic therapy. Because mortality and complications are unusual in 
patients with FD, the assessment of QOL was used as the measure of the outcome 
and primary and secondary end points. 
PATIENTS AND METHODS 
Study Design 
This 1-year, single-center, prospective, open-label, controlled, parallel-group 
trial was conducted at the Department of Gastroenterology, Ferencv~ros Health 
Centre, Budapest, Hungary. The study protocol was approved by the local 
ethics committee and conformed to the principles in the Declaration of Helsinki 
and its amendments. 3 
Study Population 
Male and female Hpylori-positive (HP+) and Hpylori-negative (HP-) patients 
with FD and healthy subjects (control) were enrolled. The inclusion criteria 
were age between 20 and 60 years and the presence of dyspepsia ccording 
to the Rome II criteria. 2Patients were excluded if they had any other chron- 
ic organic diseases that could alter QOL and that required drug treatment 
(eg, severe hypertension, myocardial ischemia/infarction, congestive heart fail- 
ure, diabetes mellitus, renal failure, cirrhosis, previous gastric surgery [resec- 
tion, vagotomy], biliary stone disease, chronic pancreatitis, chronic obstruc- 
tive pulmonary disease, rheumatoid arthritis, heavy drinking [>5 alcoholic 
beverages/d]) or regular use of nonsteroidal anti-inflammatory drugs (eg, 
acetylsalicylic acid, naproxen, indomethacin, diclofenac, celecoxib, meloxicam, 
nabumetone) or bisphosphonates (eg, alendronate). 
In dyspeptic patients, organic diseases were ruled out using endoscopy 
(Fujinon UGI FP7, Fuji Photo Optical Co. Ltd., Saitasma, Japan) and abdominal 
ultrasonography (Sonoline Prima, Siemens AG, Munich, Germany). The diagno- 
sis of H pylori infection was confirmed on biopsy using modified Giemsa stain 
and a rapid urease test (Controloc Test kit, Byk-Gulden [now ALTANA Pharma 
AG], Konstanz, Germany). HP- patients were not retested using any other 
method (eg, serology, breath test). 
Healthy controls were enrolled from among individuals referred by Dimension 
Insurance Ltd., Budapest, Hungary, which conducts biennial fee-for-service gas- 
troenterologic screening consisting of a medical history, physical examination, 
abdominal ultrasonography, and basic laboratory studies (complete blood 
count, glucose concentration, lipid profile, kidney function, C-reactive protein, 
307 
CURRENT THERAPEUTIC RESEARCH 
and liver enzymes). The controls were not tested for H pylori before inclusion 
in the QOL study. 
QOL was assessed using the Functional Digestive Disorders Quality of Life 
(FDDQoL) Questionnaire developed by the MAPI Research Institute (Lyon, 
France) 4 and translated and validated in Hungarian 5 to have psychometric 
properties similar to those of the original version. The questionnaire 
includes 43 items organized in 8 domains: daily activities (8 items), anxiety 
level (5), diet (6), sleep (3), discomfort (9), coping with disease (6), disease 
control (3), and the influence of stress (3). Answer options comprised 5- and 
6-point Likert scales. The questionnaire was self-administered to all partici- 
pants at baseline and at 6 weeks and 1 year after H pylori eradication or 
cisapride therapy. 
Written informed consent was obtained from all participants. Three visits 
(baseline, 6 weeks, and 1 year) were required for the dyspeptic patients and 
1 visit (baseline) for the controls. 
Study Drug Administration 
The study design is shown in Figure 1. 
All drugs in this study were self-administered as tablets. HP+ patients re- 
ceived pantoprazole 40 mg BID + amoxicillin 1000 mg BID + clarithromycin 
500 mg BID for 7 days, followed by on-demand ranitidine 150-300 mg/d during 
the 1-year follow-up period. A control 13C-urea breath test using isotope- 
selective infrared spectrometry (IRIS C13, Wagner Analysentechnik GmbH, 
Bremen, Germany) was performed 6 weeks after eradication. The patients were 
blinded to the results of their eradication status before they completed the 
questionnaire. HP- patients received cisapride 10 mg TID for 1 month followed 
by on-demand cisapride 10-20 mg/d for 1 year. Compliance was assessed using 
a pill count during the short-term treatment and by self-reporting during the 
maintenance period. Ranitidine or cisapride use (mg/wk) was estimated based 
on patients' reports. 
Statistical Analysis 
A sample size of 78 patients in each group was calculated for a power of 80% 
to detect a 15% difference between groups. The raw scores were calculated. 
After standardization and linear transformation of the raw scores (STSs), a 
scale of 0 to 100 points was obtained (the higher the value, the better the QOL). 
The normal range of the STS QOL scores was defined as the mean (SD) of the 
values found in the healthy controls. The 95% CIs were determined for the STS 
scores. Differences between the groups and the change over time in both 
groups of patients with FD were calculated using analysis of variance (ANOVA), 
and P values <0.05 were considered significant. The post-hoc Tukey test was 
used when appropriate. Differences in QOL domain scores were also assessed 
using ANOVA. The influence of demographic variables on QOL was assessed 
using multiple ogistic regression analysis. Eradication results were expressed 
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on intent-to-treat (ITT) and per-protocol (PP) bases. For items that were missing 
or not applicable, case regression imputation was used as appropriate; for miss- 
ing questionnaires, simple mean imputation was performed. The effect size was 
defined as the difference between the mean score of the week-6 and baseline 
QOL assessments divided by the SD of the baseline measurement. 6 Between- 
group differences were calculated using the 2-tailed t test. 6 The statistics were 
calculated using Statistica version 9.0 (StatSoft, Inc., Tulsa, Oklahoma). 
RESULTS 
A total of 101 HP÷ patients, 98 HP- patients with FD, and 123 healthy controls 
were included in the study (185 women, 137 men; mean age, 39.0 years). The 
baseline demographic data for the 3 groups are given in Table I. 
The mean (SD) baseline STS QOL scores were significantly lower in the HP÷ 
group (53.3 [9.6]; 95% CI, 54.4-58.2) and HP-group (50.0 [9.8]; 95% CI, 58.0-62.0) 
compared with that in the healthy controls (76.2 [8.7]; 95% CI, 74.6-77.8) (both, 
P < 0.001) (Table II and Figure 2). The normal STS QOL range (70.9-81.5) was 
the value found in the healthy controls. The baseline QOL domain values are 
shown in Table II. 
Effects of Eradication Therapy on Quality of Life 
H pylori was eradicated in 77/101 (76.2%) of patients on ITT analysis and 
77/94 (81.9%) on PP analysis. In successfully treated cases, the mean (SD) STS 
QOL scores increased from 56.2 (9.8) (95% CI, 53.9-58.4) to 70.8 (10.7) (95% CI, 
63.3-73.2) at 6 weeks (P< 0.001 vs baseline) and to 75.3 (9.3) (95% CI, 73.2-77.5) 
Table I. Baseline demographic and clinical characteristics of the study population 
(N = 322).* 
HP+ HP- Control 
Characteristic (n = 101) (n = 98) (n = 123) 
Age, y 
Mean (SD) 38.6 (11.6) 39.3 (12.4) 39.2 (11.0) 
Range 18-72 20-67 21-64 
Sex, no. (%) 
Female 67 (66.3) 62 (63.3) 56 (45.5) 
Male 34 (33.7) 36 (36.7) 67 (54.5) 
Disease duration 
of complaints, mean (SD), y 3.4 (3.4) 3.2 (3.7) - 
Smoking, no (%) 50 (49.5) 49 (50.5) 34 (27.6) 
Alcohol use, no (%)t 20 (19.8) 14 (14.3) 19 (15.4) 
H P + = Helicobacter pylori positive; H P- = Helicobacter pylori negative. 
*No significant between-group differences were found. 
tHeavy drinkers (>5 alcoholic beverages/d) were excluded from the study. 
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Table II. Baseline distribution of the domain scores on the Functional Digestive Dis- 
orders Quality of Life (QOL) Questionnaire 4. in patients with Helicobacterpylori- 
positive (HP+) and -negative (HP-) functional dyspepsia and healthy subjects 
(control). Data are mean standardized scores after linear transformation 
(950/0 C0. 
HP+ HP- Control 
QOL Domain (n = 101) (n = 98) (n = 123) 
Daily activities 54.6 54.9 79.9 
(50.6-58.5) t (51.4-58.4) t (77.1-82.1 ) 
Anxiety level 51.8 49.9 67.7 
(48.1-55.5){ (46.7-53.3)§ (65.0-70.4) 
Diet 53.7 56.6 70.8 
(50.9-56.7) t (53.5-59.7) t (68.6-73.2) 
Sleep 55.3 56.6 64.9 
(49.6-63.0) t (54.0-59.1)t (64.1-65.8) 
Discomfort 51.2 55.3 63.7 
(48.6-53.7) t (52.5-58.1)t (61.5-65.9) 
Coping with disease 45.4 46.4 46.5 
(42.6-48.2) (43.7-49.0) (44.0-49.0) 
Disease control 53.9 51.5 59.7 
(51.1-56.9) t (48.4-54.7) t (57.4-61.9) 
Stress 56.3 50.2 56.4 
(54.4-58.2) (47.1-53.3) t (53.8-58.9) 
Global scoresll 53.3 (9.6) 50.0 (9.8) 76.2 (8.7) 
(54.4-58.2) t (58.0-62.0) t (74.6-77.8) 
*The questionnaire scale includes 43 items organized in 8 domains: daily activities (8 items), anxiety 
level (5), diet (6), sleep (3), discomfort (9), coping with disease (6), disease control (3), and theinflu- 
ence of stress (3). Answer options comprise 5- and 6-point Likert scales. 
tp < 0.001 versus controls. 
~P = 0.011 versus controls. 
§P = 0.022 versus controls. 
IIMean (SD) (95% CI). 
at 1 year (P = 0.05 vs 6 weeks) (Figure 3). In patients with persistent infection, 
the STS QOL scores were 53.3 (95% CI, 54.4-58.2) at baseline and 56.0 (95% CI, 
49.9-62.1) at 6 weeks. These patients underwent second-and third-line thera- 
pies and were not considered for analysis at 1 year. 
The changes over time in the domain scores are shown in Table III. Analysis 
of the domain scores found that FD was associated with impairment of almost 
all domains of QOL (ie, daily activities, anxiety level, diet, sleep, discomfort, dis- 
ease control, and stress). There was no significant difference in the domain of 
coping with FD. The profile of QOL impairment and its reversal after treatment 
was similar between the HP+ and HP- patients; the HP+ group had significantly 
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decreased scores in 6 of 8 domains: daily activities (P = 0.005), anxiety level 
(P= 0.02), diet (P= 0.008), sleep (P< 0.001), discomfort (P= 0.004), and disease 
control (P = 0.02); the HP- group had significantly decreased scores in 5 of 
8 domains: daily activities (P< 0.001), diet (P = 0.004), sleep (P = 0.005), discom- 
fort (P < 0.001), and disease control (P = 0.02). At 1-year follow-up, only disease 
control increased significantly in HP+ patients, and stress in HP- patients. 
The compliance rate was 88% at 6 weeks and 74% at i year. During the follow- 
up period, the mean dose of ranitidine was 150 mg TIW. 
The short-term effect size was 1.48 in HP+ and 1.35 in HP- patients (Table IV). 
Effects of  Cisapride on Quality of  Life 
In the HP- group, mean (SD) STS QOL increased from 50.0 (9.8) (95% CI, 58.0-62.0) 
at baseline to 73.3 (9.7) (95% CI, 71.3-75.4) at 6 weeks of cisapride treatment (P < 
0.001) and to 76.5 (8.5) (95% CI, 74.5-78.4) at i year (P = 0.06 vs 6 weeks) (Figure 4). 
The changes over time in the domain scores are shown in Table III. 
The compliance rate was 92% at 6 weeks and 78% at i year. During the follow- 
up period, the mean dose of cisapride was 40 mg/wk. 
The effect size was large after short-term therapy and small during mainte- 
nance treatment (Table IV). 
Multiple logistic regression analysis showed that increasing age (r = 0.30; P = 
0.07) and female sex (r = 0.23; P = 0.04) were associated with QOL in HP- patients 
with FD at baseline; after cisapride therapy, only age was associated with QOL 
(r = 0.38; P = 0.01). No such effect was observed in HP+ patients. Smoking, 
alcohol consumption, and duration of complaints were not associated with 
changes in QOL before or after treatment in either group. 
Tolerability 
Adverse events (AEs) occurred in 22 (21.8%) patients in the HP+ group (nau- 
sea, 8 [7.9%] patients; diarrhea, 5 [5.0%]; loss of appetite, 5 [5.0%]; stomatitis, 5
[5.0%]; abdominal pain, 4 [4.0%]; bloating, 4 [4.0%]; headache, 4 [4.0%]; vomit- 
Table IV. Effect size of Helicobacter pylori  eradication and cisapride 
treatment in patients with functional dyspepsia.* 
Group n Effect Size 
HP÷ 
Short-term successful eradication 
On-demand ranitidine for 1 year 
HP- 
Short-term cisapride therapy 
On-demand cisapride for 1 year 
101 
82 1.48 
74 0.68 
98 
93 1.35 
77 0.34 
H P + = Helicobacter pylori positive; H P- = Helicobacter pylori negative. 
*No significant between-group differences were found. 
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Figure 4. 
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ing, 4 [4.0%]; constipation, 3 [3.0%]; and vaginitis, 3 [3.0%]). In the HP- group, 
AEs occurred in 9 (9.2%) patients (abdominal cramps, 7 [7.1%]; diarrhea, 4 
[4.1%]; and nausea, 3 [3.1%]). No cardiac AEs were reported in either group. 
One HP÷ patients and 2 HP- patients discontinued treatment because of 
vaginitis and severe diarrhea, respectively. 
DISCUSSION 
Several disease-specific QOL instruments have been developed, 7-12 but all have 
some methodologic flaws. 13,14 The FDDQoL has acceptable r liability and validity, 
but its sensitivity to capture treatment effects has been found only in irritable 
bowel disease. 4 
QOL has been found to be impaired in some patients with FD. 1'4'7-12 The 
degree of functional impairment is similar to or more severe than in organic dis- 
eases (eg, ulcer, reflux disease). 11Subtypes of FD may be associated with differ- 
ent patterns and/or severity of impairment. 11 The results of the present study 
suggest hat QOL is impaired in patients with FD compared with healthy con- 
trois. Because only investigated cases were included, the patients in the pres- 
ent study did not represent the entire dyspeptic population. It was not possible 
to distinguish patients with and without H pylori infection based on QOL data, 
which is supported by the findings in a previous clinical study. 15 
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The isolated improvements in QOL domains--disease control in HP+ 
patients and stress in HP- patients--found at 1-year follow-up are difficult to 
explain. Demographic variables (age and female sex) had a modest influence on 
QOL in HP- patients with FD. Impairment might have been caused by the dys- 
peptic symptoms themselves and not by other factors (eg, smoking, alcohol 
consumption). 
The European consensus report 16 on the management of H pylori infection 
recommends eradication of Hpylori in individuals with FD after a full investiga- 
tion. Meta-analyses of clinical trials in patients with FD have found that eradica- 
tion was associated with a minor improvement in dyspeptic symptoms. 17,18 
Other studies, however, have found variable levels of symptomatic relief and 
improvement in QOL in subgroups of FD patients. 19-22 In primary care settings, 
eradication of H pylori improved symptoms and QOL in Canadian, 23,24 British, 25 
Finnish, 26 and Japanese populations, 27,28 and was found to be cost-effective in 
Canada and the United Kingdom. 24,29 Lack of benefit of eradicating the infection 
in patients with FD was reported in the United Kingdom, 29 Spain, 3° Denmark, 31 
and Mexico. 32 The use of different QOL instruments in different populations 
might explain the divergent findings. 
In the present study, H pylori eradication was associated with significant 
improvements in short- and long-term QOL (7 of 8 domains) and in dyspeptic 
symptoms. The effect size was large after 6 weeks; on-demand maintenance 
treatment did not add to the 1-year improvement in QOL. Some arguments favor 
the eradication policy (eg, the prevention of subsequent occurrences of peptic 
ulcer/gastric cancer, decreases in the prevalence of the infection and the infec- 
tious reservoir of the population). One-week triple therapy achieved a high rate 
of eradication, as suggested by international standards. 16FD is a chronic, recur- 
rent disorder, and follow-up lasting >1 year may be needed before declaring a 
definitive improvement in QOL after eradication. Studies of long-term follow-up of 
5 years in 100 cases and 7 years in 201 patients with FD found either symptomatic 
resolution and prevention of disease progression 33,34 or persistence ofdyspepsia 
over a long period after H pylori eradication. 35 We plan to follow up the patients 
in the present study for 3 to 5 years, with the results expected in 2007 or 2008. 
Two studies have found a favorable ffect of cisapride in FD. 36'37 However, 
symptom improvement was variable, and the results in patients recruited from 
primary care were negative. 1,2 In a recent systematic review, prokinetics were 
found to be superior to placebo for FD therapy, 38 but only a limited number of 
agents of this class can currently be prescribed. 39Studies assessing QOL in 
patients with FD who are receiving prokinetic therapy are scarce. In 1 such 
study, in which symptom severity and QOL were improved after 1 year of cis- 
apride therapy in 57 patients with FD, only generic instruments were used. 4° In 
a randomized trial in 512 patients with FD, symptom relief was significantly 
improved with omeprazole compared with cisapride, ranitidine, and placebo; 
however, no QOL assessment was undertaken. 41 None of these studies deter- 
mined whether the prokinetic effect was dependent on Hpylori status. 
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This study supports the short- and long-term benefits of cisapride treatment 
in HP- patients with FD. The effect size of prokinetic therapy was large after 
short-term and small after maintenance therapy. However, the favorable results 
are overshadowed by the proarrhythmic AE of cisapride42; for this reason, the 
drug was withdrawn from the markets in Europe and the United States. FDDQoL 
is a valuable instrument for assessing QOL and might be used in the future for 
the evaluation of emergent prokinetic therapies. For instance, in an Australian 
study in 554 patients with FD, dyspeptic symptoms were more improved with 
the dopamine D2 receptor antagonist itopride compared with placebo. 43 
The present study had some limitations. Because the study was performed 
in clinical practice, the inclusion of a placebo or untreated HP+ or HP- control 
group during the active phase of the trial was considered unethical and would 
have violated the European and the Hungarian consensus tatements. 16,44 In 
addition, the study was not randomized because the patients were included in 
the HP+ or HP- group a priori. 
Even with these limitations, the results support a QOL benefit of eradicating 
H pylori in patients with FD. Prokinetic treatment also proved to be useful for 
improving QOL in HP- patients with FD. 
Nonetheless, FD treatment has some unresolved caveats; the optimal ther- 
apy is still unclear. New pathogenetic hypotheses are arising and a better 
understanding of abnormalities underlying FD may lead to improved disease 
management. 45~7 We believe that assessment of QOL will have a place in the 
evaluation of novel therapies. 
CONCLUSIONS 
In this study in patients with FD, eradication of H pylori infection in infected 
patients and cisapride treatment in uninfected patients reversed low QOL 
scores and improved global QOL during the 1-year follow-up period. 
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